½ÃÀ庸°í¼­
»óǰÄÚµå
1750847

¼¼°èÀÇ µðÁöÅРȣÈí±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ÀûÀÀÁõº°, À¯Åëä³Îº°, ÃÖÁ¾¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)

Digital Respiratory Devices Market Size, Share & Trends Analysis Report By Product (Smart Inhalers & Nebulizers, Sensors & Apps), By Disease Indication, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ µðÁöÅРȣÈí±â ½ÃÀå ±Ô¸ð¿Í µ¿Çâ

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è µðÁöÅРȣÈí±â ½ÃÀå ±Ô¸ð´Â 2025-2030³â±îÁö 28.92%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇϸç, 2030³â¿¡´Â 3,042¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¹è°æ¿¡´Â ¸¸¼º Æó»ö¼º Æó Áúȯ(COPD), õ½Ä, ³¶Æ÷¼º ¼¶À¯Áõ, Æó Áúȯ µîÀÇ ¸¸¼º È£Èí±â Áúȯ(CRD) ȯÀÚ Áõ°¡°¡ ÀÖ½À´Ï´Ù. Æó Äɾ À§ÇÑ Çõ½ÅÀûÀÎ µðÁöÅÐ ±â±â¿Í ½Ã½ºÅÛ Áõ°¡¸¦ ÃËÁøÇÏ°í µðÁöÅРȣÈí±â ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ »õ·Î¿î °Ë»ç´Â COVID-19 ¹ÙÀÌ·¯½ºÀÇ Á¸À縦 °¨ÁöÇϱâ À§ÇØ ½º¸¶Æ®ÆùÀÇ µµ¿òÀ¸·Î ±âħ ¼Ò¸®¸¦ »ç¿ëÇÕ´Ï´Ù.

°Ô´Ù°¡ COVID-19ÀÇ À¯Çà Áß, Áø´ÜÀ̳ª Ä¡·á¸¦ Á÷Á¢ ¹ÞÁö ¸øÇÑ È¯ÀÚµµ ÀÖ¾ú½À´Ï´Ù. À¯Çà ÈÄÀÇ ½Ã´ë¿¡´Â ȯÀÚ°¡ »óȲ¿¡ °ü°è¾øÀÌ °¡´ÉÇÑ ÃÖ»óÀÇ Äɾî¿Í Áø·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï Çϱâ À§ÇØ, ÀÇ·á Àü¹®°¡°¡ Ä¿³ØÆ¼µå ÀÇ·á±â±â¿¡ ´«À» µ¹¸®°Ô µÇ¾î ½º¸¶Æ® ÈíÀÔ±âÀÇ Ã¤¿ëÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°Ô´Ù°¡ µðÁöÅРȣÈí±â ºÐ¾ß¿¡¼­ÀÇ ±â¼úÀû Áøº¸ Áõ°¡´Â õ½Ä°ú COPDÀÇ °ü¸®»Ó¸¸ ¾Æ´Ï¶ó, Åõ¾àÀÇ È¿À²À» °³¼±Çϱâ À§ÇØ ±âÁ¸ Á¦Ç° Æ÷Æ®Æú¸®¿À¿¡ µðÁöÅÐ ±â¼úÀ» ½ºÄÉÀÏ ¾÷Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù ¿¬±¸´Â ½º¸¶Æ® ÈíÀԱ⠱â¼úÀÌÀÌ ¹®Á¦¸¦ ÇØ°áÇϰí ȯÀÚ¿¡°Ô Ä¡·á ±ÔÁ¤ Áؼö¸¦ À¯ÁöÇϰí Áõ»óÀ» Á¦¾îÇÏ´Â °£´ÜÇÑ ¹æ¹ýÀ» Á¦°øÇÒ ¼öÀÖ´Â °¡´É¼ºÀ» º¸¿©ÁÝ´Ï´Ù. Cleveland ClinicÀÇ 2019³â ¿¬±¸¿¡¼­ Propeller ½º¸¶Æ® ÈíÀԱ⸦ ÀÌ¿ëÇÑ COPD ȯÀÚ´Â Àü³â(2020³â)¿¡ ºñÇØ ¹æ¹®ÀÌ 35% °¡±îÀÌ °¨¼ÒÇßÀ¸¸ç ÀÔ¿ø À§ÇèÀÌ ÇöÀúÈ÷ ³·¾Ò½À´Ï´Ù.

µðÁöÅРȣÈí±â ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2024³â ½º¸¶Æ® ÈíÀÔ±â ¹× ºÐ¹«±â°¡ Á¦Ç°º°·Î 63.97% ÀÌ»óÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • 2024³â¿¡´Â ÀûÀÀÁõº°·Î´Â COPD ºÎ¹®ÀÌ 51.39% ÀÌ»óÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • À¯Åë ä³Îº°·Î´Â º´¿ø ¾à±¹ÀÌ 2024³â¿¡ 38.31% ÃʰúÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • 2024³â¿¡´Â ÃÖÁ¾ ¿ëµµº°·Î º´¿øÀÌ 51.32% ÀÌ»óÀÇ ÃÖ´ëÀÇ ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • 2024³â¿¡´Â ºÏ¹Ì°¡ 47.33% ÀÌ»óÀÇ Á¡À¯À²À» Â÷ÁöÇÏ°í ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ÀÌ´Â ³ëÀÎ Àα¸ÀÇ È£Èí±â Áúȯ Áõ°¡, À¯¸®ÇÑ »óȯ ¸®º£ÀÌÆ® µî Á¤ºÎ ±ÔÁ¦ÀÇ »õ·Î¿î °³Á¤ ¹× È®¸³µÈ °Ç°­ °ü¸® ÀÎÇÁ¶ó ¶§¹®ÀÔ´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¼ºÀåÀº Áß±¹°ú Àεµ¿¡¼­ COPD¿Í õ½ÄÀÇ ÀÌȯÀ²ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹üÀ§¿Í ¸ñÀû

Á¦2Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹æ¹ý
  • Á¤º¸ Á¶´Þ
    • ±¸ÀÔÇÑ µ¥ÀÌÅͺ£À̽º
    • GvrÀÇ ³»ºÎ µ¥ÀÌÅͺ£À̽º
    • 2Â÷ Á¤º¸
    • 1Â÷ Á¶»ç
  • Á¤º¸ ¶Ç´Â µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ ºÐ¼® ¸ðµ¨
  • ½ÃÀåÀÇ Ã¥Á¤°ú °ËÁõ
  • ¸ðµ¨ÀÇ »ó¼¼
    • »óǰ È帧 ºÐ¼®(¸ðµ¨ 1)
    • ¼ö·® °¡°Ý ºÐ¼®(¸ðµ¨ 2)
  • 2Â÷ Á¤º¸ ¸®½ºÆ®

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅëÀÇ Àü¸Á
    • ¸ð ½ÃÀå Àü¸Á
    • º¸Á¶ ½ÃÀå Àü¸Á
  • µðÁöÅРȣÈí±â: ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • µðÁöÅРȣÈí±â ½ÃÀå : ºñÁî´Ï½º ȯ°æ ºÐ¼® µµ±¸
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
  • ħÅõ¿Í ¼ºÀåÀÇ Àü¸Á ¸ÅÇÎ
  • ±â¼ú µ¿Ç⠺м®
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
  • COVID-19¿¡ ÀÇÇÑ µðÁöÅРȣÈí±â ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå µðÁöÅРȣÈí±â ½ÃÀå : Á¦Ç°º° ºÐ¼®

  • µðÁöÅРȣÈí±â ½ÃÀå : Á¡À¯À² ºÐ¼®, 2021³â ¹× 2030³â
  • µðÁöÅРȣÈí±â ½ÃÀå : ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м® : Á¦Ç°º°, 2017-2030³â

Á¦6Àå µðÁöÅРȣÈí±â ½ÃÀå : ÀûÀÀÁõº° ºÐ¼®

  • µðÁöÅРȣÈí±â ½ÃÀå : Á¡À¯À² ºÐ¼®, 2021³â ¹× 2030³â
  • µðÁöÅРȣÈí±â ½ÃÀå : ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м® : ÀûÀÀÁõº°, 2017-2030³â

Á¦7Àå µðÁöÅРȣÈí±â ½ÃÀå : À¯Åë ä³Îº° ºÐ¼®

  • µðÁöÅРȣÈí±â ½ÃÀå : Á¡À¯À² ºÐ¼®, 2021³â ¹× 2030³â
  • µðÁöÅРȣÈí±â ½ÃÀå : ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м® : À¯Åëä³Îº°, 2017-2030³â

Á¦8Àå µðÁöÅРȣÈí±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ºÐ¼®

  • µðÁöÅРȣÈí±â ½ÃÀå : Á¡À¯À² ºÐ¼®, 2021³â ¹× 2030³â
  • µðÁöÅРȣÈí±â ½ÃÀå : ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м® : ÃÖÁ¾ ¿ëµµº°, 2017-2030³â

Á¦9Àå µðÁöÅРȣÈí±â ½ÃÀå : Áö¿ª ºÐ¼®

  • µðÁöÅРȣÈí±â ½ÃÀå : Á¡À¯À² ºÐ¼®, 2021³â ¹× 2030³â
  • Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)

Á¦10Àå °æÀï ºÐ¼®

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • COHERO HEALTH, INC.
    • COGNITA LABS
    • ADHERIUM LIMITED
    • AMIKO DIGITAL HEALTH LIMITED
    • TEVA PHARMACEUTICALS INDUSTRIES LTD.
    • PROPELLER HEALTH
    • NOVARTIS AG
    • PNEUMA RESPIRATORY, INC.
    • 3M HEALTH CARE LIMITED
    • FINDAIR SP. Z OO
    • AIREHEALTH, INC.
>JHS

Digital Respiratory Devices Market Growth & Trends:

The global digital respiratory devices market size is expected to reach USD 304.28 billion by 2030, registering a CAGR of 28.92% from 2025 to 2030, based on a new report by Grand View Research, Inc. The market growth can be attributed to an increase in the number of people with chronic respiratory diseases (CRDs) such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, and lung disorders. Moreover, COVID-19 has prompted a rise in the number of innovative digital devices and systems for respiratory and pulmonary care, which is driving the demand for digital respiratory devices. For instance, in March 2022, Brisbane-based ResApp informed about the positive data that it received from the Covid-19 instant screening test. The coughing sound is used with the help of a smartphone to detect the presence of the COVID-19 virus in the new test.

Furthermore, during the COVID-19 outbreak, several patients were unable to receive consultations and treatments in person. The pandemic demonstrated how serious respiratory illnesses and infections may become if not treated quickly and carefully. As a result of this, in the post-pandemic era, smart inhaler adoption is anticipated to increase as healthcare professionals turn to connected medical devices to ensure that patients receive the best care and consultation possible, regardless of the circumstance.

Additionally, a growing number of technological advancements in the field of digital respiratory devices are scaling up the digital technologies into existing product portfolios to improve the efficiency of medication as well as the management of asthma and COPD. Moreover, recent studies conducted by research experts have shown that smart inhaler technology may be able to resolve this problem and offer patients a simple way to keep up treatment compliance and control symptoms. For example, a 2019 study from the Cleveland Clinic found that COPD patients utilizing Propeller smart inhalers had a significantly lower risk of being admitted to the hospital, with a nearly 35% drop in visits compared to the previous year (2020).

Digital Respiratory Devices Market Report Highlights:

  • In 2024, the smart inhalers and nebulizers product segment held the largest revenue share of over 63.97% owing to the prevalence of asthma and other respiratory conditions rising in direct proportion to air pollution levels, which, in turn, drives the demand for smart inhalers and nebulizers.
  • In 2024, the COPD indication segment held the largest revenue share of over 51.39%. The growth of the COPD segment can be attributed to people continuing to smoke and longer life expectancies
  • The hospital pharmacies distribution channel segment accounted for the largest revenue share of over 38.31% in 2024. The older population is regularly hospitalized in hospitals for various chronic respiratory illnesses, and they obtain medicine from hospital pharmacies for such conditions.
  • In 2024, the hospitals end-use segment accounted for the largest revenue share of over 51.32%. The rising rates of chronic respiratory diseases among developing nations and the rising aging population suffering from asthma and COPD are contributing to the segment growth
  • In 2024, North America dominated the market with a share of over 47.33% owing to increasing respiratory disorders among the senior population, new amendments in the government regulations such as favorable reimbursement rebates, and well-established healthcare infrastructure.
  • The Asia Pacific is projected to register fastest CAGR over the forecast period. This growth can be attributed to growing COPD and asthma incidence rates in China and India.

Table of Contents

Chapter 1 Report Scope and Objectives

  • 1.1 Market Segmentation & Scope
  • 1.2 Regional Scope
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Objectives
    • 1.3.1 Objective - 1
    • 1.3.2 Objective - 2
    • 1.3.3 Objective - 3

Chapter 2 Methodology

  • 2.1 Research Methodology
  • 2.2 Information Procurement
    • 2.2.1 Purchased Database
    • 2.2.2 Gvr's Internal Database
    • 2.2.3 Secondary Sources
    • 2.2.4 Primary Research
  • 2.3 Information Or Data Analysis
    • 2.3.1 Data Analysis Models
  • 2.4 Market Formulation & Validation
  • 2.5 Model Details
    • 2.5.1 Commodity Flow Analysis (Model 1)
    • 2.5.2 Volume Price Analysis (Model 2)
  • 2.6 List Of Secondary Sources

Chapter 3 Executive Summary

  • 3.1 Market Outlook
  • 3.2 Segment Outlook
    • 3.2.1 Product
    • 3.2.2 Indication
    • 3.2.3 Distribution Channel
    • 3.2.4 End Use
    • 3.2.5 Region
  • 3.3 Competitive Insights
  • 3.4 Digital Respiratory Devices Market Outlook, 2021

Chapter 4 Market Variables, Trends & Scope

  • 4.1 Market Lineage Outlook
    • 4.1.1 Parent Market Outlook
    • 4.1.2 Ancillary Market Outlook
  • 4.2 Digital Respiratory Devices Market Dynamics
    • 4.2.1 Market Driver Analysis
    • 4.2.2 Market Restraint Analysis
  • 4.3 Digital Respiratory Devices Market: Business Environment Analysis Tools
    • 4.3.1 Porter's Five Forces Analysis
      • 4.3.1.1 Threat of new entrants
      • 4.3.1.2 Bargaining power of suppliers
      • 4.3.1.3 Bargaining power of buyers
      • 4.3.1.4 Competitive rivalry
      • 4.3.1.5 Threat of substitutes
    • 4.3.2 PESTEL Analysis
      • 4.3.2.1 Political & Legal
      • 4.3.2.2 Economic & Social
      • 4.3.2.3 Technological
      • 4.3.2.4 Environmental
  • 4.4 Penetration & Growth Prospect Mapping
  • 4.5 Technology Trend Analysis
  • 4.6 Regulatory Framework
  • 4.7 Impact of COVID-19 on Digital Respiratory Devices Market

Chapter 5 Digital Respiratory Devices Market: Product Analysis

  • 5.1 Digital Respiratory Devices Product Market Share Analysis, 2021 & 2030
  • 5.2 Digital Respiratory Devices Product Market: Segment Dashboard
  • 5.3 Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the Product Segment
    • 5.3.1 Sensors And Apps
      • 5.3.1.1 sensors And Apps Market, 2017 - 2030 (USD Million)
    • 5.3.2 Smart Inhalers And Nebulizers
      • 5.3.2.1 Smart inhalers and nebulizers market, 2017 - 2030 (USD Million)

Chapter 6 Digital Respiratory Devices Market: Indication Analysis

  • 6.1 Digital Respiratory Devices Indication Market Share Analysis, 2021 & 2030
  • 6.2 Digital Respiratory Devices Indication Market: Segment Dashboard
  • 6.3 Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the Indication Segment
    • 6.3.1 Asthma
      • 6.3.1.1 Asthma market, 2017- 2030 (USD Million)
    • 6.3.2 COPD
      • 6.3.2.1 COPD market, 2017 - 2030 (USD Million)
    • 6.3.3 Others
      • 6.3.3.1 Others market, 2017- 2030 (USD Million)

Chapter 7 Digital Respiratory Devices Market: Distribution Channel Analysis

  • 7.1 Digital Respiratory Devices Distribution Channel Market Share Analysis, 2021 & 2030
  • 7.2 Digital Respiratory Devices Distribution Channel Market: Segment Dashboard
  • 7.3 Market Size & Forecasts And Trend Analyses, 2017 To 2030 For The Distribution Channel
    • 7.3.1 Hospitals Pharmacies
      • 7.3.1.1 Hospitals Pharmacies Market, 2017- 2030 (USD Million)
    • 7.3.2 Retail Pharmacies
      • 7.3.2.1 Retail Pharmacies Market, 2017 - 2030 (USD Million)
    • 7.3.3 Online Pharmacies
      • 7.3.3.1 Online pharmacies market, 2017- 2030 (USD Million)

Chapter 8 Digital Respiratory Devices Type Market: END-USE Analysis

  • 8.1 Digital Respiratory Devices Type Market Share Analysis, 2021 & 2030
  • 8.2 Digital Respiratory Devices End-Use Market: Segment Dashboard
  • 8.3 Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the End-Use Segment
    • 8.3.1 Hospitals
      • 8.3.1.1 Hospitals Market, 2017- 2030 (USD Million)
    • 8.3.2 Homecare Settings
      • 8.3.2.1 Homecare Settings Market, 2017- 2030 (USD Million)
    • 8.3.3 Other Settings
      • 8.3.3.1 Other settings market, 2017- 2030 (USD Million)

Chapter 9 Digital Respiratory Devices Market: Regional Analysis

  • 9.1 Digital Respiratory Devices Regional Market Share Analysis, 2021 & 2030
  • 9.2 Regional Market Snapshot
  • 9.3 North America
    • 9.3.1 North America Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.3.2 U.S.
      • 9.3.2.1 U.S. Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.3.3 Canada
      • 9.3.3.1 Canada digital respiratory devices market, 2017 - 2030 (USD Million)
  • 9.4 Europe
    • 9.4.1 Europe Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.4.2 U.K.
      • 9.4.2.1 U.K. Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.4.3 Germany
      • 9.4.3.1 Germany Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.4.4 France
      • 9.4.4.1 France digital respiratory devices market, 2017 - 2030 (USD Million)
    • 9.4.5 Italy
      • 9.4.5.1 Italy digital respiratory devices market, 2017 - 2030 (USD Million)
    • 9.4.6 Spain
      • 9.4.6.1 Spain Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
  • 9.5 Asia Pacific
    • 9.5.1 Asia Pacific Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.5.2 Japan
      • 9.5.2.1 Japan Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.5.3 China
      • 9.5.3.1 China Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.5.4 India
      • 9.5.4.1 India digital respiratory devices market, 2017 - 2030 (USD Million)
  • 9.6 Latin America
    • 9.6.1 Latin America Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.6.2 Brazil
      • 9.6.2.1 Brazil Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.6.3 Mexico
      • 9.6.3.1 Mexico Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
  • 9.7 Middle East And Africa (Mea)
    • 9.7.1 Mea Digital Respiratory Devices Market, 2017 - 2030 (USD Million)
    • 9.7.2 South Africa
      • 9.7.2.1 South Africa digital respiratory devices market, 2017 - 2030 (USD Million)

Chapter 10 Competitive Analysis

  • 10.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2 Company Profiles
    • 10.2.1 COHERO HEALTH, INC.
      • 10.2.1.1 Company overview
      • 10.2.1.2 Financial performance
      • 10.2.1.3 Product benchmarking
      • 10.2.1.4 Strategic initiatives
    • 10.2.2 COGNITA LABS
      • 10.2.2.1 Company overview
      • 10.2.2.2 Financial performance
      • 10.2.2.3 Product benchmarking
      • 10.2.2.4 Strategic initiatives
    • 10.2.3 ADHERIUM LIMITED
      • 10.2.3.1 Company overview
      • 10.2.3.2 Financial performance
      • 10.2.3.3 Product benchmarking
      • 10.2.3.4 Strategic initiatives
    • 10.2.4 AMIKO DIGITAL HEALTH LIMITED
      • 10.2.4.1 Company overview
      • 10.2.4.2 Financial performance
      • 10.2.4.3 Product benchmarking
      • 10.2.4.4 Strategic initiatives
    • 10.2.5 TEVA PHARMACEUTICALS INDUSTRIES LTD.
      • 10.2.5.1 Company overview
      • 10.2.5.2 Financial performance
      • 10.2.5.3 Product benchmarking
      • 10.2.5.4 Strategic initiatives
    • 10.2.6 PROPELLER HEALTH
      • 10.2.6.1 Company overview
      • 10.2.6.2 Financial performance
      • 10.2.6.3 Product benchmarking
      • 10.2.6.4 Strategic initiatives
    • 10.2.7 NOVARTIS AG
      • 10.2.7.1 Company overview
      • 10.2.7.2 Financial performance
      • 10.2.7.3 Product benchmarking
      • 10.2.7.4 Strategic initiatives
    • 10.2.8 PNEUMA RESPIRATORY, INC.
      • 10.2.8.1 Company overview
      • 10.2.8.2 Financial performance
      • 10.2.8.3 Product benchmarking
      • 10.2.8.4 Strategic initiatives
    • 10.2.9 3M HEALTH CARE LIMITED
      • 10.2.9.1 Company overview
      • 10.2.9.2 Financial performance
      • 10.2.9.3 Product benchmarking
      • 10.2.9.4 Strategic initiatives
    • 10.2.10 FINDAIR SP. Z O.O.
      • 10.2.10.1 Company overview
      • 10.2.10.2 Financial performance
      • 10.2.10.3 Product benchmarking
      • 10.2.10.4 Strategic initiatives
    • 10.2.11 AIREHEALTH, INC.
      • 10.2.11.1 Company overview
      • 10.2.11.2 Financial performance
      • 10.2.11.3 Product benchmarking
      • 10.2.11.4 Strategic initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦